Brain Implant Delivers Artificial Vision Directly to the Cortex

2026-10-31 bio

Haarlem, Saturday, 31 October 2026.
Dutch startup Phosphoenix secured €1.3 million to advance clinical trials for a brain implant that bypasses damaged eyes, using over 1,000 micro-electrodes to restore functional sight.

Pioneering Neuroprosthetics in Healthtech

Within the convergence of medicine and healthtech, restorative neurotechnology is emerging as a critical frontier for untreatable sensory conditions [1]. Dutch medical technology startup Phosphoenix is spearheading this shift with an artificial intelligence-driven neuroprosthetic device engineered to restore functional vision to patients experiencing late-onset, progressive blindness [1]. By entering a field where biological restoration options are fundamentally exhausted, this innovation offers substantial patient benefits, specifically fostering personal autonomy and reducing dependence on continuous external care for individuals whose visual pathways have degraded [1].

Academic Roots and Leadership in Amsterdam

The foundation of this technology originates in Amsterdam through close ties with the Netherlands Institute for Neuroscience [1]. Leadership of the venture is split between academic research and commercial execution: Prof. Pieter Roelfsema serves as co-founder and Chief Scientific Officer, while Hans Brons leads the venture as Chief Executive Officer [1][2][4]. Roelfsema has compared the functionality of the neural interface to an electrical matrix board, illustrating the mechanical transition required when converting academic laboratory findings into a regulated medical device [2]. Phosphoenix continues to leverage the local research ecosystem, participating alongside regional life science leaders at platforms such as the Life Science Health Capital Match scheduled for November 5, 2026, at Matrix ONE in Amsterdam Science Park [4][7].

Bypassing Ocular Damage via the Fountain Probe

Conventional biological vision relies on light passing through the eyes to the retina before transmitting optical impulses to the brain [1]. In cases where irreversible degeneration destroys the optic nerve or retina—affecting a portion of the estimated 40 million individuals facing severe blindness worldwide—standard ocular interventions fail to offer restorative efficacy [1]. Phosphoenix completely circumvents the optic organs by interfacing directly with the brain using its proprietary neural hardware, the Fountain Probe™ [1].

Targeting the LGN with Electrical Micro-Stimulation

The core mechanism behind the Fountain Probe™ relies on more than 1,000 integrated micro-electrodes that deliver targeted electrical signals directly into a specific visual processing hub known as the lateral geniculate nucleus (LGN) [1]. Operating via integrated artificial intelligence algorithms, these electrical pulses trigger phosphenes—controlled perceptions of light that manifest in the patient’s field of awareness without optical input [1]. By structuring these perceived points of light into recognizable artificial patterns, the neurostimulation platform establishes an alternative pathway to functional vision [1].

Capital Roadmaps and Clinical Timelines

To move this deep-tech medical apparatus toward patient validation, Phosphoenix secured a €1.3 million funding tranche backed by regional development agency ROM InWest [1]. As stated by ROM InWest investment manager Sara Schaafsma, the investment is calibrated to speed up operational preparations for an upcoming First-in-Human (FIH) clinical study targeted for 2027 [1]. While initial project timelines anticipated preparations culminating in late 2026 [alert! ‘Early project notes cited trials starting in late 2026, but primary investment disclosures officially state first-in-human clinical testing begins in 2027’], the current capital injection directly funds the immediate technical refinements of the neurostimulation array [1].

The Bridge to Commercialization

Beyond the immediate seed-stage capital, Phosphoenix is currently structuring a Series A round to raise approximately €20 million [1]. Securing this scale of growth financing represents an expansion step from its initial €1.3 million injection, representing a projected fundraising increase of 1438.462% over the current commitment [1]. The forthcoming capital deployment will finance comprehensive multi-year clinical trial programs, steering the venture from a laboratory spin-off in Amsterdam toward international medical device commercialization [1].

Bronnen

Brain implant Visual prosthesis